A phase I, randomized, double-blinded, safety trial of high-dose nicotinamide riboside (NR) in Parkinson’s Disease. This short trial took place during the first half of 2022 and has been completed. Data are currently being analyzed and a open-access publication will be made available shortly.
Ethics approval body/ID: REK / 379218
Contact: Head Research Nurse Erika V. Sheard: +47 992 04 028, firstname.lastname@example.org